Get started
Author

Yu-Hsiang Chen

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
2020 · Milan Radovich, Guanglong Jiang, et al. · JAMA Oncology · 330
PDF
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
2017 · Yu-Hsiang Chen, Bradley A. Hancock, et al. · npj Breast Cancer · 126
PDF
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
2021 · Bryan P. Schneider, Guanglong Jiang, et al. · Journal of Clinical Oncology · 57
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
2019 · Bradley A. Hancock, Yu-Hsiang Chen, et al. · Breast Cancer Research · 37
PDF
Propyl Gallate Attenuates Methylglyoxal-Induced Alzheimer-like Cognitive Deficits and Neuroinflammation in Mice
2026 · Hui-Yun Tsai, Jing Qiu, et al. · International Journal of Molecular Sciences · 6
PDF
Propyl Gallate Mitigates Gastric Injury Caused by Indomethacin in Wistar Rats
2025 · Felix Widodo, Yun-Ya Wang, et al. · Journal of Agricultural and Food Chemistry · 2
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes
2025 · Yu-Hsiang Chen, Timothy Bi, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Abstract 711: Co-detection of circulating tumor DNA and RNA for enhanced detection of minimal residual disease in patients with chemorefractory triple-negative breast cancer
2020 · Yu-Hsiang Chen, Bradley A. Hancock, et al. · Cancer Research · 1
Abstract 2280: Co-detection of circulating tumor DNA and RNA in the plasma of patients with breast cancer increases the detectable number of mutated molecules
2019 · Yu-Hsiang Chen, Bradley A. Hancock, et al. · Cancer Research · 1
Development and Evaluation of Quality Metrics for Bioinformatics Analysis of Viral Insertion Site Data Generated Using High Throughput Sequencing
2014 · Hongyu Gao, Troy Hawkins, et al. · Biomedicines · 1
PDF
EXABS-150-MDS: Mechanisms of Measurable Residual Disease Progression for Myelodysplastic Syndromes After Allogeneic Stem Cell Transplantation
2026 · Yu-Hsiang Chen, Timothy Bi, et al. · Clinical Lymphoma Myeloma & Leukemia
Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant
2025 · Yu-Hsiang Chen, Timothy Bi, et al. · Blood
3045 – Molecular Evolution of Measurable Residual Disease in Myelodysplastic Syndromes
2024 · Yu-Hsiang Chen, Jaehyun Lee, et al. · Experimental Hematology
PDF
1649P A proof-of-concept study for detecting ctDNA in rare thyroid cancers
2022 · D.M. Vodopivec Kuri, Y.H. Chen, et al. · Annals of Oncology
Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative breast cancer
2022 · Bryan P Schneider, Guanglong Jiang, et al. · Cancer Research
Abstract P4-01-16: 4-marker positive selection system for improved circulating tumor cell analysis of metastatic triple-negative breast cancer
2020 · Bradley A. Hancock, Yuan Zhong, et al. · Cancer Research
Abstract 1354: 4-marker positive selection system for improved CTC analysis in metastatic triple-negative breast cancer
2019 · Bradley Hancock, Chun-Li Chang, et al. · Clinical Research (Excluding Clinical Trials)
Multi-Modality Plasma-Based Detection of Minimal Residual Disease in Triple-Negative Breast Cancer
2019 · Chen, Yu-Hsiang · IUScholarWorks (Indiana University)
Abstract 2280: Co-detection of circulating tumor DNA and RNA in the plasma of patients with breast cancer increases the detectable number of mutated molecules
2019 · Yu-Hsiang Chen, Bradley A. Hancock, et al. · Clinical Research (Excluding Clinical Trials)
Abstract 1354: 4-marker positive selection system for improved CTC analysis in metastatic triple-negative breast cancer
2019 · Bradley Hancock, Chun-Li Chang, et al. · Cancer Research
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
2019 · Hancock, Bradley, Yu-Hsiang Chen, et al. · Figshare
Abstract LB-138: TP53 mutation is a biomarker for prognosis in triple-negative breast cancer patients treated with post-neoadjuvant cisplatin
2016 · Bradley Hancock, Yu-Hsiang Chen, et al. · Cancer Research
Analysis of integration sites of transgenic sheep generated by lentiviral vectors using next-generation sequencing technology
2014 · Chen, Yu-Hsiang · Purdue e-Pubs (Purdue University System)
Stability of Gaa/ttc and Ctg/cag Trinucleotide Repeats During Break-induced Replication in Yeast
2012 · Yu-Hsiang Chen, Anna Malkova · IUScholarWorks (Indiana University)
Works count: 34
Citation count: 562
H-index: 5
I10-index: 4
Year
Topic
Type